Banco Bilbao Vizcaya Argentaria SA vs GeneDx Holdings Corp — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 76.9× GeneDx Holdings Corp's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BBVA | WGS | |
|---|---|---|
Market Cap | $142.30B | $1.85B |
Sector | Financials | Technology |
52-Week High | $26.14 | $167.51 |
52-Week Low | $14.73 | $34.51 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $1.85B |
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
No Aura AI signal available yet.
Trailing returns across standard periods
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →